Literature DB >> 25873170

Radiotherapy complements immune checkpoint blockade.

Shin Foong Ngiow1, Grant A McArthur2, Mark J Smyth3.   

Abstract

Adaptive immune resistance ablates effective anti-tumor immune responses. In a recent issue of Nature, Victor and colleagues describe that anti-PD-L1 combats adaptive immune resistance upon localized radiation plus anti-CTLA-4 therapy. The superior activity of radiation and dual immune checkpoint blockade is mediated by non-redundant immune mechanisms in cancer.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25873170     DOI： 10.1016/j.ccell.2015.03.015

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  18 in total

Review 1.  Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance?

Authors:  Andrea Riccardo Filippi; Jacopo Di Muzio; Serena Badellino; Cristina Mantovani; Umberto Ricardi
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 2.  Immune checkpoint inhibitors: a new frontier in bladder cancer.

Authors:  Max Kates; Nikolai A Sopko; Hotaka Matsui; Charles G Drake; Noah M Hahn; Trinity J Bivalacqua
Journal:  World J Urol       Date:  2015-10-20       Impact factor: 4.226

Review 3.  Nanoparticle-based approaches to target the lymphatic system for antitumor treatment.

Authors:  Xingzhou Peng; Junjie Wang; Feifan Zhou; Qian Liu; Zhihong Zhang
Journal:  Cell Mol Life Sci       Date:  2021-05-08       Impact factor: 9.261

Review 4.  PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future.

Authors:  T Jelinek; R Hajek
Journal:  Oncoimmunology       Date:  2016-11-08       Impact factor: 8.110

Review 5.  Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment.

Authors:  Kasturee Chakraborty; Archana Tripathi; Sukumar Mishra; Argha Mario Mallick; Rituparna Sinha Roy
Journal:  Biosci Rep       Date:  2022-07-29       Impact factor: 3.976

Review 6.  Combination cancer immunotherapies tailored to the tumour microenvironment.

Authors:  Mark J Smyth; Shin Foong Ngiow; Antoni Ribas; Michele W L Teng
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

Review 7.  Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.

Authors:  Zhong-Yi Dong; Si-Pei Wu; Ri-Qiang Liao; Shu-Mei Huang; Yi-Long Wu
Journal:  Tumour Biol       Date:  2016-01-16

8.  Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors.

Authors:  Deborah T Blumenthal; Michal Yalon; Gilad W Vainer; Alexander Lossos; Shlomit Yust; Lior Tzach; Emanuela Cagnano; Dror Limon; Felix Bokstein
Journal:  J Neurooncol       Date:  2016-07-04       Impact factor: 4.130

Review 9.  Nanotechnology synergized immunoengineering for cancer.

Authors:  Deepak S Chauhan; Anupam Dhasmana; Partha Laskar; Rajendra Prasad; Nishant K Jain; Rohit Srivastava; Meena Jaggi; Subhash C Chauhan; Murali M Yallapu
Journal:  Eur J Pharm Biopharm       Date:  2021-03-24       Impact factor: 5.589

10.  Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer.

Authors:  Jessica Nakhlé; Valérie Pierron; Anne-Laure Bauchet; Pascale Plas; Amath Thiongane; Florence Meyer-Losic; Fabien Schmidlin
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.